Bone Biologics Co. (NASDAQ:BBLG – Free Report) – Research analysts at Zacks Small Cap lifted their Q3 2024 earnings estimates for Bone Biologics in a report released on Monday, August 12th. Zacks Small Cap analyst B. Sorensen now forecasts that the company will post earnings per share of ($0.60) for the quarter, up from their previous estimate of ($1.34). The consensus estimate for Bone Biologics’ current full-year earnings is ($5.32) per share. Zacks Small Cap also issued estimates for Bone Biologics’ Q4 2024 earnings at ($0.59) EPS, FY2024 earnings at ($3.17) EPS, Q1 2025 earnings at ($0.54) EPS, Q2 2025 earnings at ($0.51) EPS, Q3 2025 earnings at ($0.55) EPS, Q4 2025 earnings at ($0.59) EPS, FY2025 earnings at ($2.19) EPS and FY2026 earnings at ($2.21) EPS.
Bone Biologics (NASDAQ:BBLG – Get Free Report) last posted its quarterly earnings results on Friday, August 9th. The company reported ($0.67) EPS for the quarter, beating the consensus estimate of ($1.39) by $0.72.
Bone Biologics Stock Up 6.5 %
Bone Biologics Company Profile
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.
Featured Articles
- Five stocks we like better than Bone Biologics
- NYSE Stocks Give Investors a Variety of Quality OptionsÂ
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- What Makes a Stock a Good Dividend Stock?
- Jeff Brown’s Exegesis AI Stock Picks
- The Role Economic Reports Play in a Successful Investment Strategy
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.